Potential Molecular Targets in the Treatment of Patients with CNS Tumors

The challenges in identifying effective therapies for CNS tumors continue to be daunting [...].

[1]  M. Ahluwalia,et al.  Combination of EGFR-Directed Tyrosine Kinase Inhibitors (EGFR-TKI) with Radiotherapy in Brain Metastases from Non-Small Cell Lung Cancer: A 2010–2019 Retrospective Cohort Study , 2023, Cancers.

[2]  M. Venere,et al.  Improving Localized Radiotherapy for Glioblastoma via Small Molecule Inhibition of KIF11 , 2023, Cancers.

[3]  M. Ahluwalia,et al.  First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases , 2023, Cancers.

[4]  M. Ahluwalia,et al.  DNA Methylation and Histone Modification in Low-Grade Gliomas: Current Understanding and Potential Clinical Targets , 2023, Cancers.

[5]  J. D. de Groot,et al.  Preclinical Models of Low-Grade Gliomas , 2023, Cancers.

[6]  M. S. Baptista,et al.  GBM Cells Exhibit Susceptibility to Metformin Treatment According to TLR4 Pathway Activation and Metabolic and Antioxidant Status , 2023, Cancers.

[7]  M. Ahluwalia,et al.  Novel Therapeutic Approaches in Neoplastic Meningitis , 2022, Cancers.

[8]  Hideo Nakamura,et al.  Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study , 2022, Cancers.

[9]  S. Cuzzocrea,et al.  Adenosine Targeting as a New Strategy to Decrease Glioblastoma Aggressiveness , 2022, Cancers.

[10]  C. Eberhart,et al.  Comprehensive Metabolic Profiling of MYC-Amplified Medulloblastoma Tumors Reveals Key Dependencies on Amino Acid, Tricarboxylic Acid and Hexosamine Pathways , 2022, Cancers.

[11]  P. Kumthekar,et al.  Updates on Molecular Targeted Therapies for Intraparenchymal CNS Metastases , 2021, Cancers.

[12]  D. Ziegler,et al.  Therapeutic Targets in Diffuse Midline Gliomas—An Emerging Landscape , 2021, Cancers.

[13]  K. Aldape,et al.  Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas , 2021, Cancers.

[14]  A. Olar,et al.  Molecular Classification and Therapeutic Targets in Ependymoma , 2021, Cancers.

[15]  L. Klesse,et al.  Targeted Therapies for the Neurofibromatoses , 2021, Cancers.

[16]  C. Grommes,et al.  Update on Novel Therapeutics for Primary CNS Lymphoma , 2021, Cancers.

[17]  J. Sampson,et al.  Enhancing T Cell Chemotaxis and Infiltration in Glioblastoma , 2021, Cancers.

[18]  M. Georgescu.  Multi-Platform Classification of IDH-Wild-Type Glioblastoma Based on ERK/MAPK Pathway: Diagnostic, Prognostic and Therapeutic Implications , 2021, Cancers.

[19]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[20]  J. Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. , 2020, Neuro-oncology.

[21]  D. Brat,et al.  Relative survival after diagnosis with a primary brain or other central nervous system tumor in the National Program of Cancer Registries, 2004 to 2014. , 2019, Neuro-oncology practice.

[22]  J. Barnholtz-Sloan,et al.  Estimating the annual frequency of synchronous brain metastasis in the United States 2010–2013: a population-based study , 2017, Journal of Neuro-Oncology.

[23]  C. Tseng,et al.  Survival in pediatric medulloblastoma: a population-based observational study to improve prognostication , 2017, Journal of Neuro-Oncology.

[24]  M. Gilbert,et al.  Biology and management of ependymomas. , 2016, Neuro-oncology.

[25]  Steven J. M. Jones,et al.  Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.

[26]  Sunit Das,et al.  IDH mutation in glioma: new insights and promises for the future. , 2014, JAMA neurology.

[27]  P. Beauchesne.  Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. , 2010, The Lancet. Oncology.

[28]  M. Loda,et al.  Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma , 2008, Cancer.

[29]  E. Thiel,et al.  Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors , 2006, Journal of Neuro-Oncology.

[30]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[31]  A. Twijnstra,et al.  Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma , 2002, Cancer.

[32]  J. Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. , 2019, Neuro-oncology.